Please assess the completion status of the following clinical trial:

Trial Title: Pilot Feasibility Study of the Safety and Efficacy of Anakinra in Heart Failure With Preserved Ejection Fraction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Symptoms and signs of congestive heart failure~* Recent Imaging Study (\<12 months) showing Left Ventricular Ejection Fraction (LVEF) \>50% and Left Ventricular End Diastolic Volume Index (LVEDVI) \<97ml/m2~* Evidence of abnormal Left Ventricular (LV) relaxation, filling, diastolic distensibility, and diastolic stiffness as shown by one of the following:~  1. Invasive Hemodynamic measurements~     * mean Pulmonary Capillary Wedge pressure (mPCW) \>12~    * Left Ventricular End Diastolic Pressure (LVEDP) \>16 mmHg~ 2. Tissue Doppler Echocardiogram~     * E/E' \>15~    * E/E' 8-15 and one of the following~       * Left Ventricular Hypertrophy (LVH)~      * Atrial Fibrillation~      * Left Atrial Enlargement~      * E/A \<0.5 + Deceleration Time (DT) \>280 (if \>50yrs of age)~ 3. Biomarkers~* Brain Natriuretic Peptide (BNP) \>200pg/mL~Exclusion Criteria:~* Age \<18~* Recent changes (previous 3 months) in HF maintenance medications (beta-blockers, angiotensin converting enzyme \[ACE\] inhibitors, aldosterone antagonists, vasodilators, cardiac glycosides, diuretics)~* Hospitalization for worsening Heart Failure (HF) or acute decompensated HF within the previous 12months~* Anticipated need for cardiac resynchronization therapy (CRT) or automated-implantable cardioverter defibrillator (AICD)~* Angina or electrocardiograph (ECG) changes that limit maximum exertion during cardiopulmonary exercise testing~* Active infection including chronic infection~* Active cancer~* Recent (\<14 days) use of anti-inflammatory drugs (not including Non-Steroidal Anti-Inflammatory Drugs \[NSAIDs\]), Chronic inflammatory disorder (including but not limited to rheumatoid arthritis, systemic lupus erythematosus), malignancy, or any comorbidity limiting survival or ability to complete the study~* Pregnancy (determined by urine pregnancy test in women of childbearing potential)~* Inability to give informed consent~* Other conditions limiting completion of cardiopulmonary exercise test or completion of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anakinra (Type: EXPERIMENTAL): Treatment with daily subcutaneous injections of Anakinra 100 mg
- Placebo (Type: PLACEBO_COMPARATOR): Treatment with daily subcutaneous injection of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).